Rawstron, A., Cairns, D., Webster, N., Dalal, S., Shingles, J., Tute, R. D., Hockaday, A., Jackson, S., Bell, S., Greatorex, N., Stones, D., Allsup, D., Bloor, A., Sarma, A., Varghese, A. M., Munir, T., Hillmen, P. (2025). Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.. Blood. https://doi.org/10.1182/blood-2025-794